Gravie, Inc. operates a health insurance platform that facilitates the comparison and purchase of health insurance plans for individuals, families, and employers. Founded in 2013 and headquartered in Minneapolis, Minnesota, the company provides a comprehensive solution for managing health insurance expenses through its mobile application and website. Gravie allows users to shop for insurance options available on government-run exchanges and directly from insurance companies. The platform also offers tools for employers to design custom benefits plans using a defined contribution approach, enabling them to set a fixed budget for employee health benefits. Additionally, Gravie provides year-round support, financial analysis, and services such as Gravie Care, which assists individuals in managing their healthcare expenses effectively.
Autonomic Technologies, Inc. is a medical device company that focuses on the development and commercialization of therapies for the treatment of autonomic disorders, particularly severe headache. It develops ATI Neurostimulation System, a device that delivers low-level energy directly to the area of the SPG for the treatment of chronic cluster headache. The company was founded in 2007 and is based in Mountain View, California with additional offices in Germany and Switzerland.
Jiff, Inc. is a technology company specializing in digital health applications and platforms designed for the healthcare industry. Established in 2010 and headquartered in Mountain View, California, Jiff provides a HIPAA-compliant environment where consumers and healthcare professionals can create personalized communities of care. The company's offerings include JiffPad, an iPad educational platform that enhances doctor-patient communication by transforming discussions and imagery into shareable videos, allowing patients to engage from home. Additionally, JiffPad connects medical professionals to a network of leaders and organizations through JiffTalks. The company aims to improve employee health engagement by linking company benefits with healthy behaviors, utilizing familiar wearables and applications. Jiff has formed strategic alliances with firms such as Towers Watson & Co. and Mercer, and it operates as a subsidiary of Castlight Health, Inc. as of 2017.
Autonomic Technologies, Inc. is a medical device company that focuses on the development and commercialization of therapies for the treatment of autonomic disorders, particularly severe headache. It develops ATI Neurostimulation System, a device that delivers low-level energy directly to the area of the SPG for the treatment of chronic cluster headache. The company was founded in 2007 and is based in Mountain View, California with additional offices in Germany and Switzerland.
Gravie, Inc. operates a health insurance platform that facilitates the comparison and purchase of health insurance plans for individuals, families, and employers. Founded in 2013 and headquartered in Minneapolis, Minnesota, the company provides a comprehensive solution for managing health insurance expenses through its mobile application and website. Gravie allows users to shop for insurance options available on government-run exchanges and directly from insurance companies. The platform also offers tools for employers to design custom benefits plans using a defined contribution approach, enabling them to set a fixed budget for employee health benefits. Additionally, Gravie provides year-round support, financial analysis, and services such as Gravie Care, which assists individuals in managing their healthcare expenses effectively.
GoBalto is a software platform that develops cloud-based solutions for drug trial sponsors and clinical research organizations. Its products offer drug trial sponsors and clinical research organizations the fastest, easiest possible way to start clinical studies on the web.
The company was founded in 2008 and headquartered in San Francisco, California.
Jiff, Inc. is a technology company specializing in digital health applications and platforms designed for the healthcare industry. Established in 2010 and headquartered in Mountain View, California, Jiff provides a HIPAA-compliant environment where consumers and healthcare professionals can create personalized communities of care. The company's offerings include JiffPad, an iPad educational platform that enhances doctor-patient communication by transforming discussions and imagery into shareable videos, allowing patients to engage from home. Additionally, JiffPad connects medical professionals to a network of leaders and organizations through JiffTalks. The company aims to improve employee health engagement by linking company benefits with healthy behaviors, utilizing familiar wearables and applications. Jiff has formed strategic alliances with firms such as Towers Watson & Co. and Mercer, and it operates as a subsidiary of Castlight Health, Inc. as of 2017.
Gravie, Inc. operates a health insurance platform that facilitates the comparison and purchase of health insurance plans for individuals, families, and employers. Founded in 2013 and headquartered in Minneapolis, Minnesota, the company provides a comprehensive solution for managing health insurance expenses through its mobile application and website. Gravie allows users to shop for insurance options available on government-run exchanges and directly from insurance companies. The platform also offers tools for employers to design custom benefits plans using a defined contribution approach, enabling them to set a fixed budget for employee health benefits. Additionally, Gravie provides year-round support, financial analysis, and services such as Gravie Care, which assists individuals in managing their healthcare expenses effectively.
GoBalto is a software platform that develops cloud-based solutions for drug trial sponsors and clinical research organizations. Its products offer drug trial sponsors and clinical research organizations the fastest, easiest possible way to start clinical studies on the web.
The company was founded in 2008 and headquartered in San Francisco, California.
Advance Medical is one of the largest, physician-based telemedicine providers, offering employers and insurers the ability to provide top-quality, concierge-level medical advice and support to patients around the globe via offices in the U.S., Europe, Asia, and South America. Founded in 1999, Advance Medical has emerged as the global leader in expert medical opinions because of its programs executed exclusively by board-certified physicians – doctors who speak by phone or video consultation with every patient, no matter what the issue or concern and for as much time as necessary, to provide best-in-class medical expertise.
Private Equity Round in 2013
Adavium Medical is a medical equipment and diagnostics company aimed at bringing commercial sophistication to a highly fragmented market. The Company was formed with the intent to commercialize the most innovative portfolio of medical device and diagnostics products in Brazil. Adavium Medical portfolio today is made up of products that we commercialize on behalf of leading international companies. Adavium Medical assembled an experienced team of more than 300 employees that ensure that its fully-integrated commercial platform operates at world-class standards. Adavium Medical have the largest customer base across premium and “long tail” customers of any medical equipment and/or diagnostics company in Brazil, with more than 2,500 customers respectively in medical equipment and diagnostics. This is exponentially more than the average distributor or multinational in the region. The company was founded in 2011 and is headquartered in Sao Paulo, Brazil.
Aviir is a venture-funded biotechnology company developing cutting-edge, diagnostic tests enabling accurate diagnosis and prognosis of cardiovascular disease. The company’s proprietary technology is based on ten years of research at Stanford University, and combines the scientific founder’s deep understanding of biomarker assay development and advanced biostatistics. Aviir has pursued an aggressive commercialization strategy, and initial products, including the MIRISK VP™ test, are currently on the market. The Aviir leadership team includes the founding scientists and highly experienced management.
Cervel Neurotech, Inc., based in San Mateo, California, is a private medical device company that specializes in non-invasive deep brain neuro-modulation. Founded in 2008 by M. Bret Schneider, MD, David J. Mishelevich, MD, PhD, and entrepreneur Michael J. Partsch, the company has developed a proprietary technology that utilizes repetitive transcranial magnetic stimulation (rTMS) to modulate brain function through magnetic fields that induce electrical currents. This innovative approach, known as Steerable TMS, allows for targeted stimulation of specific brain areas associated with psychiatric and neurological disorders, minimizing unintended effects and facilitating quicker patient treatment initiation. Cervel Neurotech's technology is based on licensed research from Stanford University and was acquired by Rio Grande Neurosciences in 2015.
Aviir is a venture-funded biotechnology company developing cutting-edge, diagnostic tests enabling accurate diagnosis and prognosis of cardiovascular disease. The company’s proprietary technology is based on ten years of research at Stanford University, and combines the scientific founder’s deep understanding of biomarker assay development and advanced biostatistics. Aviir has pursued an aggressive commercialization strategy, and initial products, including the MIRISK VP™ test, are currently on the market. The Aviir leadership team includes the founding scientists and highly experienced management.
GoBalto is a software platform that develops cloud-based solutions for drug trial sponsors and clinical research organizations. Its products offer drug trial sponsors and clinical research organizations the fastest, easiest possible way to start clinical studies on the web.
The company was founded in 2008 and headquartered in San Francisco, California.
MC10, Inc. specializes in developing and selling wearable medical sensors that capture clinical-grade biometric and physiological data for use in clinical trials. Founded in 2008 and based in Lexington, Massachusetts, the company offers several innovative products, including BioStamp nPoint, which processes raw data into clinical metrics such as vital signs and sleep patterns; Kintinuum, a rehabilitation device for orthopedic surgery; WiSP, which provides cardiac monitoring and ECG recording; and BioStampMD, a flexible sensor designed to conform to the human body for comprehensive data collection. The BioStamp system enhances data acquisition by allowing for discreet and comfortable wear, thus facilitating targeted measurements of muscle activation and movement. MC10's dedication to creating flexible, conformal electronics aims to improve the quality of life by seamlessly integrating technology with human activity.
Wello is an online platform that facilitates live fitness training through two-way video, offering users an accessible and cost-effective way to engage with fitness professionals. Launched in 2011 by Stanford MBA graduates Ann Scott Plante and Leslie Silverglide, Wello's initial product, 1-on-1 personal training, debuted in 2012. The platform connects clients with vetted trainers tailored to their specific fitness needs, ensuring a personalized experience. It simplifies the process of scheduling and payment while establishing a live video connection for workouts. In 2013, Wello participated in the Rock Health program, integrating itself into a prominent network of digital health companies. Based in San Francisco, Wello continues to provide innovative solutions for those seeking flexible and interactive fitness options.
Bluesight is a software tool developed by Kit Check, Inc. that focuses on substance tracking and drug diversion detection within hospital pharmacies. This platform is part of a broader suite of cloud-based solutions designed to enhance the efficiency of pharmacy operations, including medication tracking and kit automation. Kit Check, Inc. utilizes Internet of Things (IoT) technology to significantly reduce kit replenishment time while increasing accuracy and minimizing errors. The company serves hospitals and pharmacies throughout the United States and Canada, tracking a substantial volume of medication, which contributes to improved supply chain management and operational safety. Founded in 2011 and based in Washington, D.C., Kit Check continues to innovate in the healthcare technology sector.
RxAnte Inc. is a healthcare analytics company focused on improving medication adherence through the use of predictive analytics. Founded in 2008 and based in Portland, Maine, RxAnte provides an innovative platform that transforms claims data into actionable insights, enabling healthcare organizations to identify patients who are most likely to benefit from adherence interventions. The company's solutions allow for the targeting, management, and evaluation of adherence support initiatives, ultimately enhancing medication prescribing and adherence while improving clinical quality and reducing overall healthcare costs. As of 2014, RxAnte operates as a subsidiary of Millennium Laboratories, Inc.
Viracta Therapeutics specializes in developing innovative treatments for cancers linked to the Epstein-Barr Virus. The company is advancing its proprietary viral gene activation therapy, which aims to effectively target and address these virus-associated malignancies. In addition to its primary focus on Epstein-Barr Virus-related cancers, Viracta is also exploring opportunities to tackle other serious diseases associated with viral infections. Through its research and therapeutic advancements, the company seeks to improve outcomes for patients suffering from these challenging health conditions.
Jiff, Inc. is a technology company specializing in digital health applications and platforms designed for the healthcare industry. Established in 2010 and headquartered in Mountain View, California, Jiff provides a HIPAA-compliant environment where consumers and healthcare professionals can create personalized communities of care. The company's offerings include JiffPad, an iPad educational platform that enhances doctor-patient communication by transforming discussions and imagery into shareable videos, allowing patients to engage from home. Additionally, JiffPad connects medical professionals to a network of leaders and organizations through JiffTalks. The company aims to improve employee health engagement by linking company benefits with healthy behaviors, utilizing familiar wearables and applications. Jiff has formed strategic alliances with firms such as Towers Watson & Co. and Mercer, and it operates as a subsidiary of Castlight Health, Inc. as of 2017.
MC10, Inc. specializes in developing and selling wearable medical sensors that capture clinical-grade biometric and physiological data for use in clinical trials. Founded in 2008 and based in Lexington, Massachusetts, the company offers several innovative products, including BioStamp nPoint, which processes raw data into clinical metrics such as vital signs and sleep patterns; Kintinuum, a rehabilitation device for orthopedic surgery; WiSP, which provides cardiac monitoring and ECG recording; and BioStampMD, a flexible sensor designed to conform to the human body for comprehensive data collection. The BioStamp system enhances data acquisition by allowing for discreet and comfortable wear, thus facilitating targeted measurements of muscle activation and movement. MC10's dedication to creating flexible, conformal electronics aims to improve the quality of life by seamlessly integrating technology with human activity.
Omada Health, Inc. is a digital healthcare company that creates online programs aimed at managing chronic conditions. Founded in 2011 and headquartered in San Francisco, with an additional office in Atlanta, Omada Health helps employers and health plans identify individuals at risk for preventable chronic diseases such as prediabetes, diabetes, hypertension, and heart disease. The company offers personalized programs that adapt to the needs of participants, including services for diabetes prevention and management, hypertension, behavioral health, and musculoskeletal issues. By integrating professional health coaching, connected devices, real-time data, and personalized feedback, Omada Health strives to empower individuals to engage with their health and achieve sustainable lifestyle changes. It is recognized as the largest provider of the National Diabetes Prevention Program by the CDC.
Aviir is a venture-funded biotechnology company developing cutting-edge, diagnostic tests enabling accurate diagnosis and prognosis of cardiovascular disease. The company’s proprietary technology is based on ten years of research at Stanford University, and combines the scientific founder’s deep understanding of biomarker assay development and advanced biostatistics. Aviir has pursued an aggressive commercialization strategy, and initial products, including the MIRISK VP™ test, are currently on the market. The Aviir leadership team includes the founding scientists and highly experienced management.
Autonomic Technologies, Inc. is a medical device company that focuses on the development and commercialization of therapies for the treatment of autonomic disorders, particularly severe headache. It develops ATI Neurostimulation System, a device that delivers low-level energy directly to the area of the SPG for the treatment of chronic cluster headache. The company was founded in 2007 and is based in Mountain View, California with additional offices in Germany and Switzerland.
NxThera develops medical technologies to treat a variety of endourology conditions, including BPH. The company's technology platform utilizes a simple, minimally invasive, vapor therapy designed to measurably improve urinary flow and patient quality of life. BPH afflicts more than 32 million men in the United States.
Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. The Senza system is the only SCS system that delivers Nevro's proprietary HF10 therapy. Senza, HF10, Nevro and the Nevro logo are trademarks of Nevro.
Aviir is a venture-funded biotechnology company developing cutting-edge, diagnostic tests enabling accurate diagnosis and prognosis of cardiovascular disease. The company’s proprietary technology is based on ten years of research at Stanford University, and combines the scientific founder’s deep understanding of biomarker assay development and advanced biostatistics. Aviir has pursued an aggressive commercialization strategy, and initial products, including the MIRISK VP™ test, are currently on the market. The Aviir leadership team includes the founding scientists and highly experienced management.
Posit Science Corporation, founded in 2002 and headquartered in San Francisco, California, specializes in brain training software designed to enhance cognitive performance. The company offers clinically proven exercises through its website that focus on improving brain speed, attention, and memory. These programs leverage advances in the science of brain plasticity, which is the brain's capacity to adapt and change throughout life. By targeting the speed and accuracy of information processing, Posit Science aims to help individuals maximize their cognitive abilities and improve their performance in everyday activities. The company was previously known as Neuroscience Solutions Corporation before rebranding in January 2005.
Conatus Pharmaceuticals Inc. is a biotechnology company that specializes in developing innovative therapeutics for liver diseases and chronic conditions with significant unmet medical needs. Founded in 2005 and headquartered in San Diego, California, the company has focused on its lead product candidate, Emricasan, an orally active caspase protease inhibitor currently in Phase IIb clinical trials for various liver-related conditions, including post-orthotopic liver transplant complications and liver fibrosis linked to nonalcoholic steatohepatitis. Additionally, Conatus is advancing CTS-2090, an orally active inhibitor of caspase 1, which is in the preclinical stage for treating chronic diseases associated with inflammasome pathways. The company has also entered into a collaboration agreement with Novartis to conduct three Phase IIb clinical trials. In May 2020, Conatus Pharmaceuticals was acquired by Histogen Inc. in a reverse merger transaction.
Vertiflex Inc. is a medical device company based in Carlsbad, California, specializing in minimally invasive solutions for lumbar spinal stenosis (LSS). Founded in 2005, the company develops advanced spinal surgery technologies, including the Superion Interspinous Spacer, a titanium implant designed to provide motion preservation and indirect decompression for patients with moderate lumbar spinal stenosis. Additionally, Vertiflex offers the Totalis Direct Decompression System, which includes specialized instruments for performing minimally invasive direct decompression of the lumbar spine. By focusing on procedures that minimize tissue trauma, Vertiflex aims to bridge the gap between conservative care and traditional spine surgery, enhancing treatment options for patients suffering from lumbar stenosis. As of June 2019, Vertiflex operates as a subsidiary of Boston Scientific Corporation.
Rock Health is a venture capital firm based in San Francisco, California, that specializes in investing in early-stage digital health startups. Founded in 2010, the firm focuses on supporting entrepreneurs who are developing innovative solutions at the intersection of healthcare and technology. It provides funding, access to a network of venture and corporate partners, legal support, and office space to its portfolio companies. Rock Health aims to invest in companies that create health-oriented products, such as activity-tracking devices, telemedicine applications, and data analytics tools that improve healthcare outcomes and reduce costs. Its notable portfolio includes startups like Omada Health, Collective Health, and Doctor on Demand, which are dedicated to enhancing healthcare accessibility and effectiveness. The firm typically considers investments ranging from $0.1 to $0.25 million per company.
Jiff, Inc. is a technology company specializing in digital health applications and platforms designed for the healthcare industry. Established in 2010 and headquartered in Mountain View, California, Jiff provides a HIPAA-compliant environment where consumers and healthcare professionals can create personalized communities of care. The company's offerings include JiffPad, an iPad educational platform that enhances doctor-patient communication by transforming discussions and imagery into shareable videos, allowing patients to engage from home. Additionally, JiffPad connects medical professionals to a network of leaders and organizations through JiffTalks. The company aims to improve employee health engagement by linking company benefits with healthy behaviors, utilizing familiar wearables and applications. Jiff has formed strategic alliances with firms such as Towers Watson & Co. and Mercer, and it operates as a subsidiary of Castlight Health, Inc. as of 2017.
EnteroMedics® Inc. is the developer of vBloc® neurometabolic therapy, delivered by a pacemaker-like device called the Maestro® Rechargeable System, a first-in-class weight loss treatment for obesity and obesity related risk factors, such as high blood pressure or high cholesterol levels. vBloc Therapy is a non-anatomy altering or restricting, reversible therapy that allows patients to safely lose weight by helping patients feel less hungry, reduce the amount of food eaten at a meal, and feel full longer in between meals.
Viracta Therapeutics specializes in developing innovative treatments for cancers linked to the Epstein-Barr Virus. The company is advancing its proprietary viral gene activation therapy, which aims to effectively target and address these virus-associated malignancies. In addition to its primary focus on Epstein-Barr Virus-related cancers, Viracta is also exploring opportunities to tackle other serious diseases associated with viral infections. Through its research and therapeutic advancements, the company seeks to improve outcomes for patients suffering from these challenging health conditions.
Aviir is a venture-funded biotechnology company developing cutting-edge, diagnostic tests enabling accurate diagnosis and prognosis of cardiovascular disease. The company’s proprietary technology is based on ten years of research at Stanford University, and combines the scientific founder’s deep understanding of biomarker assay development and advanced biostatistics. Aviir has pursued an aggressive commercialization strategy, and initial products, including the MIRISK VP™ test, are currently on the market. The Aviir leadership team includes the founding scientists and highly experienced management.
Aviir is a venture-funded biotechnology company developing cutting-edge, diagnostic tests enabling accurate diagnosis and prognosis of cardiovascular disease. The company’s proprietary technology is based on ten years of research at Stanford University, and combines the scientific founder’s deep understanding of biomarker assay development and advanced biostatistics. Aviir has pursued an aggressive commercialization strategy, and initial products, including the MIRISK VP™ test, are currently on the market. The Aviir leadership team includes the founding scientists and highly experienced management.
Aviir is a venture-funded biotechnology company developing cutting-edge, diagnostic tests enabling accurate diagnosis and prognosis of cardiovascular disease. The company’s proprietary technology is based on ten years of research at Stanford University, and combines the scientific founder’s deep understanding of biomarker assay development and advanced biostatistics. Aviir has pursued an aggressive commercialization strategy, and initial products, including the MIRISK VP™ test, are currently on the market. The Aviir leadership team includes the founding scientists and highly experienced management.
Clovis Oncology, Inc. is a biopharmaceutical company dedicated to the acquisition, development, and commercialization of anti-cancer agents in the United States, Europe, and other international markets. The company is known for its product Rubraca (rucaparib), an oral small molecule inhibitor designed to treat recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. Additionally, Clovis is developing lucitanib, an oral inhibitor that targets various tyrosine kinase receptors associated with tumor growth. The company utilizes precision medicine and companion diagnostics to ensure that therapies are directed toward patients most likely to benefit from them. Clovis Oncology distributes its products primarily through specialty distributors and pharmacy providers. Founded in 2009 and headquartered in Boulder, Colorado, the company has established partnerships and licensing agreements with multiple pharmaceutical organizations, enhancing its ability to innovate within the oncology sector.
Posit Science Corporation, founded in 2002 and headquartered in San Francisco, California, specializes in brain training software designed to enhance cognitive performance. The company offers clinically proven exercises through its website that focus on improving brain speed, attention, and memory. These programs leverage advances in the science of brain plasticity, which is the brain's capacity to adapt and change throughout life. By targeting the speed and accuracy of information processing, Posit Science aims to help individuals maximize their cognitive abilities and improve their performance in everyday activities. The company was previously known as Neuroscience Solutions Corporation before rebranding in January 2005.
Mpex Pharmaceuticals is a biopharmaceutical company developing new therapies to combat the growing issue of antibiotic resistance, with a particular focus on gram-negative organisms. The Company's internal development pipeline focuses on combining proprietary formulations, PK/PD strategies and novel potentiating agents with proven antibiotics to overcome or directly inhibit the molecular mechanisms in bacteria responsible for antibiotic resistance.
Anacor Pharmaceuticals is a biopharmaceutical company that engages in developing small-molecule therapeutics from its boron chemistry platform. It focuses on developing topical applications of its compounds to treat fungal, bacterial, and inflammatory diseases.
The company’s primary product candidate, AN2690, is a novel topical antifungal for the treatment of toenail onychomycosis, a fungal infection of the nail and nail bed. It is also developing AN2728, an anti-inflammatory product candidate for the treatment of psoriasis; AN0128, a product candidate that has antibiotic and anti-inflammatory properties; and AN2718, which is in preclinical development for the topical treatment of vaginal candidiasis and tineapedis.
Aviir is a venture-funded biotechnology company developing cutting-edge, diagnostic tests enabling accurate diagnosis and prognosis of cardiovascular disease. The company’s proprietary technology is based on ten years of research at Stanford University, and combines the scientific founder’s deep understanding of biomarker assay development and advanced biostatistics. Aviir has pursued an aggressive commercialization strategy, and initial products, including the MIRISK VP™ test, are currently on the market. The Aviir leadership team includes the founding scientists and highly experienced management.
Nevro Corp. is a medical device company that focuses on developing innovative solutions for patients suffering from chronic pain. Based in Redwood City, California, the company has created the Senza spinal cord stimulation (SCS) system, which is an evidence-based neuromodulation platform that includes the proprietary HF10 therapy. This therapy provides electrical impulses to alleviate pain and is controlled by patients through a remote device. Nevro's product offerings extend to the Senza II and Senza Omnia systems, which are designed for chronic pain management. The company markets its products primarily in the United States and utilizes a direct sales force, along with a network of sales agents and independent distributors, to reach its customers. Founded in 2006, Nevro aims to enhance the quality of life for individuals affected by debilitating pain through its advanced medical technologies.
Cervel Neurotech, Inc., based in San Mateo, California, is a private medical device company that specializes in non-invasive deep brain neuro-modulation. Founded in 2008 by M. Bret Schneider, MD, David J. Mishelevich, MD, PhD, and entrepreneur Michael J. Partsch, the company has developed a proprietary technology that utilizes repetitive transcranial magnetic stimulation (rTMS) to modulate brain function through magnetic fields that induce electrical currents. This innovative approach, known as Steerable TMS, allows for targeted stimulation of specific brain areas associated with psychiatric and neurological disorders, minimizing unintended effects and facilitating quicker patient treatment initiation. Cervel Neurotech's technology is based on licensed research from Stanford University and was acquired by Rio Grande Neurosciences in 2015.
Vertiflex Inc. is a medical device company based in Carlsbad, California, specializing in minimally invasive solutions for lumbar spinal stenosis (LSS). Founded in 2005, the company develops advanced spinal surgery technologies, including the Superion Interspinous Spacer, a titanium implant designed to provide motion preservation and indirect decompression for patients with moderate lumbar spinal stenosis. Additionally, Vertiflex offers the Totalis Direct Decompression System, which includes specialized instruments for performing minimally invasive direct decompression of the lumbar spine. By focusing on procedures that minimize tissue trauma, Vertiflex aims to bridge the gap between conservative care and traditional spine surgery, enhancing treatment options for patients suffering from lumbar stenosis. As of June 2019, Vertiflex operates as a subsidiary of Boston Scientific Corporation.
Aviir is a venture-funded biotechnology company developing cutting-edge, diagnostic tests enabling accurate diagnosis and prognosis of cardiovascular disease. The company’s proprietary technology is based on ten years of research at Stanford University, and combines the scientific founder’s deep understanding of biomarker assay development and advanced biostatistics. Aviir has pursued an aggressive commercialization strategy, and initial products, including the MIRISK VP™ test, are currently on the market. The Aviir leadership team includes the founding scientists and highly experienced management.
Aviir is a venture-funded biotechnology company developing cutting-edge, diagnostic tests enabling accurate diagnosis and prognosis of cardiovascular disease. The company’s proprietary technology is based on ten years of research at Stanford University, and combines the scientific founder’s deep understanding of biomarker assay development and advanced biostatistics. Aviir has pursued an aggressive commercialization strategy, and initial products, including the MIRISK VP™ test, are currently on the market. The Aviir leadership team includes the founding scientists and highly experienced management.
Ablation Frontiers
Series C in 2007
Ablation Frontiers, Inc. (www.ablationfrontiers.com) is a medical device company based in Carlsbad, Calif., dedicated to helping individuals suffering from AF and other cardiac arrhythmias. In 2006, Ablation Frontiers received CE Mark to begin marketing its system of catheters and the GENius™ Radiofrequency (RF) Generator in the European Union to treat supraventricular arrhythmias and for use in atrioventricular node ablation. Ablation Frontiers is conducting a clinical trial under a United States Food and Drug Administration (FDA) investigational device exemption (IDE) to gain approval of the catheter system for permanent/long-standing persistent/chronic AF in the United States. Ablation Frontiers products are not approved for marketing or sales in the United States.
Paracor Medical is a medical device company established in 1999 that specializes in developing innovative, technology-driven solutions for the treatment of heart failure. The company focuses on creating alternatives to traditional open chest surgery, aiming to alleviate the burden on patients with failing heart muscles. By employing a mechanical approach, Paracor Medical seeks to enhance the effectiveness of heart failure treatment while minimizing the invasiveness of procedures.
Conatus Pharmaceuticals Inc. is a biotechnology company that specializes in developing innovative therapeutics for liver diseases and chronic conditions with significant unmet medical needs. Founded in 2005 and headquartered in San Diego, California, the company has focused on its lead product candidate, Emricasan, an orally active caspase protease inhibitor currently in Phase IIb clinical trials for various liver-related conditions, including post-orthotopic liver transplant complications and liver fibrosis linked to nonalcoholic steatohepatitis. Additionally, Conatus is advancing CTS-2090, an orally active inhibitor of caspase 1, which is in the preclinical stage for treating chronic diseases associated with inflammasome pathways. The company has also entered into a collaboration agreement with Novartis to conduct three Phase IIb clinical trials. In May 2020, Conatus Pharmaceuticals was acquired by Histogen Inc. in a reverse merger transaction.
Vertiflex Inc. is a medical device company based in Carlsbad, California, specializing in minimally invasive solutions for lumbar spinal stenosis (LSS). Founded in 2005, the company develops advanced spinal surgery technologies, including the Superion Interspinous Spacer, a titanium implant designed to provide motion preservation and indirect decompression for patients with moderate lumbar spinal stenosis. Additionally, Vertiflex offers the Totalis Direct Decompression System, which includes specialized instruments for performing minimally invasive direct decompression of the lumbar spine. By focusing on procedures that minimize tissue trauma, Vertiflex aims to bridge the gap between conservative care and traditional spine surgery, enhancing treatment options for patients suffering from lumbar stenosis. As of June 2019, Vertiflex operates as a subsidiary of Boston Scientific Corporation.
Sequoia Pharmaceuticals is a private, venture-capital funded company founded in 2002. They are engaged in the discovery and development of novel antiviral therapeutics with a focus on combating drug-resistant HIV and HCV. They are also developing pharmacokinetic enhancers to improve the exposure of co-administered therapeutics.
Nevro Corp. is a medical device company that focuses on developing innovative solutions for patients suffering from chronic pain. Based in Redwood City, California, the company has created the Senza spinal cord stimulation (SCS) system, which is an evidence-based neuromodulation platform that includes the proprietary HF10 therapy. This therapy provides electrical impulses to alleviate pain and is controlled by patients through a remote device. Nevro's product offerings extend to the Senza II and Senza Omnia systems, which are designed for chronic pain management. The company markets its products primarily in the United States and utilizes a direct sales force, along with a network of sales agents and independent distributors, to reach its customers. Founded in 2006, Nevro aims to enhance the quality of life for individuals affected by debilitating pain through its advanced medical technologies.
NBI Development is an implantable medical device company focused on the development of novel neuromodulation therapies. The company develops Neuromodulation, the use of electrical impulses to manage activity in the nervous system.
Posit Science Corporation, founded in 2002 and headquartered in San Francisco, California, specializes in brain training software designed to enhance cognitive performance. The company offers clinically proven exercises through its website that focus on improving brain speed, attention, and memory. These programs leverage advances in the science of brain plasticity, which is the brain's capacity to adapt and change throughout life. By targeting the speed and accuracy of information processing, Posit Science aims to help individuals maximize their cognitive abilities and improve their performance in everyday activities. The company was previously known as Neuroscience Solutions Corporation before rebranding in January 2005.
Kémia operates as a pharmaceutical company. The company discovers and develops small molecule therapeutics. It offers allosteric kinase inhibitors for the treatment of inflammatory diseases, such as rheumatoid arthritis, as well as for cardiovascular and metabolic conditions; and modulators of G protein-coupled receptors. The company specializes in the fields of medicinal and analytical chemistry, biology, pharmacology, pharmacokinetics, pharmacodynamics, and clinical development.
Eledon Pharmaceuticals, Inc. is a specialty pharmaceutical company dedicated to developing products for patients with ear, nose, and throat disorders. The company's lead product, OP0201, is a surfactant-based nasal aerosol designed for individuals at risk of or suffering from otitis media, which is inflammation of the middle ear. In addition to OP0201, Eledon has developed foam-based drug delivery technologies, OP0101 and OP0102, aimed at administering medications to the ear, nose, and sinus cavities. Founded in 2004 and initially known as Novus Therapeutics, the company rebranded in January 2021 and is headquartered in Irvine, California.
KAI Pharmaceuticals is a drug discovery and development company focused on creating innovative therapeutics for cardiovascular disease, kidney disease, and pain management. The company's lead product candidate, KAI-9803, is undergoing a Phase 2b clinical trial aimed at evaluating its ability to reduce myocardial injury in patients experiencing heart attacks. Additionally, KAI is advancing its second core program, KAI-4169, which targets secondary hyperparathyroidism in kidney disease patients and is anticipated to enter human clinical trials. The company is also exploring pain management through its ongoing program, KAI-1678, currently in Phase 2a testing.
Mpex Pharmaceuticals is a biopharmaceutical company developing new therapies to combat the growing issue of antibiotic resistance, with a particular focus on gram-negative organisms. The Company's internal development pipeline focuses on combining proprietary formulations, PK/PD strategies and novel potentiating agents with proven antibiotics to overcome or directly inhibit the molecular mechanisms in bacteria responsible for antibiotic resistance.
Vertiflex Inc. is a medical device company based in Carlsbad, California, specializing in minimally invasive solutions for lumbar spinal stenosis (LSS). Founded in 2005, the company develops advanced spinal surgery technologies, including the Superion Interspinous Spacer, a titanium implant designed to provide motion preservation and indirect decompression for patients with moderate lumbar spinal stenosis. Additionally, Vertiflex offers the Totalis Direct Decompression System, which includes specialized instruments for performing minimally invasive direct decompression of the lumbar spine. By focusing on procedures that minimize tissue trauma, Vertiflex aims to bridge the gap between conservative care and traditional spine surgery, enhancing treatment options for patients suffering from lumbar stenosis. As of June 2019, Vertiflex operates as a subsidiary of Boston Scientific Corporation.
Anacor Pharmaceuticals is a biopharmaceutical company that engages in developing small-molecule therapeutics from its boron chemistry platform. It focuses on developing topical applications of its compounds to treat fungal, bacterial, and inflammatory diseases.
The company’s primary product candidate, AN2690, is a novel topical antifungal for the treatment of toenail onychomycosis, a fungal infection of the nail and nail bed. It is also developing AN2728, an anti-inflammatory product candidate for the treatment of psoriasis; AN0128, a product candidate that has antibiotic and anti-inflammatory properties; and AN2718, which is in preclinical development for the topical treatment of vaginal candidiasis and tineapedis.
Sequoia Pharmaceuticals is a private, venture-capital funded company founded in 2002. They are engaged in the discovery and development of novel antiviral therapeutics with a focus on combating drug-resistant HIV and HCV. They are also developing pharmacokinetic enhancers to improve the exposure of co-administered therapeutics.
IDUN Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of human therapeutics to control apoptosis. Its products under Phase 2 and preclinical trials include drugs for liver disease, CNS diseases, inflammation, and cancer, as well as IDN-6556 for the treatment of liver diseases in patients infected with Hepatitis C virus. The company was founded in 1993 and is based in San Diego, California. As of July 30, 2010, IDUN Pharmaceuticals, Inc. operates as a subsidiary of Conatus Pharmaceuticals Inc.
Anacor Pharmaceuticals is a biopharmaceutical company that engages in developing small-molecule therapeutics from its boron chemistry platform. It focuses on developing topical applications of its compounds to treat fungal, bacterial, and inflammatory diseases.
The company’s primary product candidate, AN2690, is a novel topical antifungal for the treatment of toenail onychomycosis, a fungal infection of the nail and nail bed. It is also developing AN2728, an anti-inflammatory product candidate for the treatment of psoriasis; AN0128, a product candidate that has antibiotic and anti-inflammatory properties; and AN2718, which is in preclinical development for the topical treatment of vaginal candidiasis and tineapedis.
Anacor Pharmaceuticals is a biopharmaceutical company that engages in developing small-molecule therapeutics from its boron chemistry platform. It focuses on developing topical applications of its compounds to treat fungal, bacterial, and inflammatory diseases.
The company’s primary product candidate, AN2690, is a novel topical antifungal for the treatment of toenail onychomycosis, a fungal infection of the nail and nail bed. It is also developing AN2728, an anti-inflammatory product candidate for the treatment of psoriasis; AN0128, a product candidate that has antibiotic and anti-inflammatory properties; and AN2718, which is in preclinical development for the topical treatment of vaginal candidiasis and tineapedis.
Salmedix is an oncology drug development company with a commercial focus on the treatment of hematologic malignancies, or blood cancers. Its primary product, SDX-105, is marketed by healthcare professionals in Germany for the treatment of several types of blood cancers. Salmedix conducts Phase II clinical trials for SDX-105 in the U.S. and Canada. Its other clinical-stage product candidates, SDX-101 and SDX-102, each with significant prior human clinical experience, are also in Phase II development. Founded in 2000 by David Kabakoff, Salmedix is headquartered in San Diego, California.
Pharmion
Venture Round in 2001
Pharmion is a global biotech company that is dedicated to the hematology and oncology communities. We work in partnership with a network of scientific and clinical advisors to identify and develop products for global hematology and oncology markets. To expand each product's potential, we have established our own regulatory, development and sales and marketing organizations in the United States, Europe, and Australia, and we have developed a third-party distributor network to serve the hematology and oncology markets in 20 additional countries throughout the Middle East, Asia, and Latin America. The global capabilities within our sales, marketing and distribution organization distinguishes us from other companies of a similar size. With our international network we can reach physicians and their patients in more than 30 countries. With proven development and regulatory professionals and an experienced global commercialization team, we concentrate our resources on licensing, developing, and commercializing therapeutic products for the treatment of hematology and oncology patients. Through these efforts, we seek to provide greater therapeutic options to hematologists and oncologists with the ultimate goal of extending survival and improving patients’ quality of life.
Microbia an industrial biotechnology company, engages in the development, production, and commercialization of specialty ingredients and biomaterials utilizing fermentation technology. Its products include carotenoids, specialty ingredients, biopolymers, and other biomaterials. The company has a strategic alliance with Tate & Lyle Investments, Ltd. to develop and commercialize fermentation-derived renewable ingredients.
Alibris is a leading online marketplace that specializes in connecting independent sellers of new and used books, music, and movies with consumers. Established in November 1998, the platform offers access to over 150 million items, including rare and collectible titles, sourced from thousands of sellers globally. Alibris serves as a vital resource for book and music enthusiasts by providing a diverse selection of used, new, and out-of-print materials. The website functions as a hub for buyers seeking unique and hard-to-find items, fostering a community of independent sellers and customers who share a passion for literature and media.
CapitalThinking is a mortgage financial services company that offers fixed and flexible payment solutions. It offers an online platform that enables its customers to apply and obtain quotations. CapitalThinking is acquired by CapitalStream in January 2004. CapitalThinking was founded in 1999 and is based in New York.